| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/22/2023 | 121.3% | Mizuho | $35 → $16 | Maintains | Buy |
| 11/09/2023 | 480.91% | Piper Sandler | $44 → $42 | Maintains | Overweight |
| 11/09/2023 | 245.78% | Needham | $35 → $25 | Maintains | Buy |
| 11/06/2023 | 107.47% | HC Wainwright & Co. | $41 → $15 | Maintains | Buy |
| 10/23/2023 | 384.09% | Barclays | $40 → $35 | Maintains | Overweight |
| 10/11/2023 | 65.98% | Morgan Stanley | $25 → $12 | Maintains | Equal-Weight |
| 09/21/2023 | 356.43% | Goldman Sachs | $38 → $33 | Maintains | Buy |
| 09/20/2023 | 508.58% | Piper Sandler | $50 → $44 | Maintains | Overweight |
| 09/20/2023 | 467.08% | HC Wainwright & Co. | → $41 | Reiterates | Buy → Buy |
| 09/20/2023 | 384.09% | Needham | $40 → $35 | Maintains | Buy |
| 08/16/2023 | 176.63% | Exane BNP Paribas | → $20 | Upgrades | Underperform → Neutral |
| 08/15/2023 | 467.08% | HC Wainwright & Co. | → $41 | Reiterates | Buy → Buy |
| 08/14/2023 | 453.25% | Needham | $40 → $40 | Reiterates | Buy → Buy |
| 08/09/2023 | 245.78% | Morgan Stanley | $26 → $25 | Maintains | Equal-Weight |
| 08/09/2023 | 453.25% | Needham | $44 → $40 | Maintains | Buy |
| 08/09/2023 | 467.08% | HC Wainwright & Co. | $48 → $41 | Maintains | Buy |
| 07/11/2023 | 259.61% | Morgan Stanley | $26 → $26 | Reiterates | Equal-Weight → Equal-Weight |
| 06/07/2023 | 384.09% | Mizuho | $33 → $35 | Maintains | Buy |
| 05/10/2023 | 508.58% | Needham | $40 → $44 | Maintains | Buy |
| 05/10/2023 | 563.9% | HC Wainwright & Co. | $42 → $48 | Maintains | Buy |
| 04/19/2023 | 453.25% | Needham | → $40 | Reiterates | → Buy |
| 04/11/2023 | 480.91% | HC Wainwright & Co. | → $42 | Reiterates | → Buy |
| 03/01/2023 | 453.25% | Barclays | $37 → $40 | Maintains | Overweight |
| 03/01/2023 | 453.25% | Needham | $38 → $40 | Maintains | Buy |
| 03/01/2023 | 480.91% | HC Wainwright & Co. | → $42 | Reiterates | → Buy |
| 01/31/2023 | 453.25% | Piper Sandler | $29 → $40 | Maintains | Overweight |
| 01/26/2023 | 480.91% | HC Wainwright & Co. | $29 → $42 | Maintains | Buy |
| 01/24/2023 | 259.61% | Morgan Stanley | $25 → $26 | Maintains | Equal-Weight |
| 01/10/2023 | 425.59% | Needham | $35 → $38 | Maintains | Buy |
| 11/16/2022 | 411.76% | Barclays | $35 → $37 | Maintains | Overweight |
| 11/09/2022 | 245.78% | Morgan Stanley | $27 → $25 | Maintains | Equal-Weight |
| 10/11/2022 | 273.44% | Morgan Stanley | → $27 | Initiates Coverage On | → Equal-Weight |
| 09/22/2022 | 356.43% | Goldman Sachs | → $33 | Initiates Coverage On | → Buy |
| 09/09/2022 | 314.94% | Mizuho | $26 → $30 | Maintains | Buy |
| 09/09/2022 | 384.09% | Barclays | $22 → $35 | Maintains | Overweight |
| 09/09/2022 | 301.11% | HC Wainwright & Co. | $25 → $29 | Maintains | Buy |
| 09/09/2022 | 384.09% | Needham | $25 → $35 | Maintains | Buy |
| 08/25/2022 | 231.95% | Wells Fargo | $17 → $24 | Maintains | Equal-Weight |
| 05/11/2022 | 259.61% | Mizuho | → $26 | Maintains | Buy |
| 10/26/2021 | 204.29% | Barclays | $33 → $22 | Maintains | Overweight |
| 10/25/2021 | 135.13% | Wells Fargo | → $17 | Downgrades | Overweight → Equal-Weight |
| 10/18/2021 | 245.78% | Needham | $45 → $25 | Maintains | Buy |
| 10/18/2021 | 148.96% | HC Wainwright & Co. | $26 → $18 | Maintains | Buy |
| 10/13/2021 | 259.61% | HC Wainwright & Co. | $35 → $26 | Maintains | Buy |
| 08/06/2021 | 356.43% | Barclays | $32 → $33 | Maintains | Overweight |
| 02/23/2021 | 384.09% | HC Wainwright & Co. | $33 → $35 | Maintains | Buy |
| 01/08/2021 | 522.41% | Needham | $42 → $45 | Maintains | Buy |
| 10/15/2020 | 480.91% | Needham | $36 → $42 | Maintains | Buy |
| 04/16/2020 | 328.77% | Stifel | $35 → $31 | Maintains | Buy |
| 04/01/2020 | 384.09% | Mizuho | $39 → $35 | Maintains | Buy |
| 03/27/2020 | 231.95% | HC Wainwright & Co. | $28 → $24 | Reiterates | → Buy |
| 03/23/2020 | 107.47% | Goldman Sachs | $32 → $15 | Downgrades | Buy → Neutral |
| 02/25/2020 | 453.25% | Piper Sandler | $37 → $40 | Reiterates | → Overweight |
| 02/25/2020 | 397.93% | Needham | $32 → $36 | Maintains | Buy |
| 02/18/2020 | 411.76% | Piper Sandler | $38 → $37 | Maintains | Overweight |
| 01/23/2020 | 439.42% | Mizuho | $34 → $39 | Maintains | Buy |
| 12/02/2019 | 245.78% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
| 10/30/2019 | 176.63% | Wells Fargo | $12.5 → $20 | Upgrades | Market Perform → Outperform |
| 06/11/2019 | 287.28% | Barclays | → $28 | Initiates Coverage On | → Overweight |
| 02/15/2019 | — | Wells Fargo | Initiates Coverage On | → Market Perform | |
| 02/14/2019 | 245.78% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 01/29/2019 | 591.56% | Stifel | → $50 | Initiates Coverage On | → Buy |
What is the target price for Revance Therapeutics (RVNC)?
The latest price target for Revance Therapeutics (NASDAQ: RVNC) was reported by Mizuho on November 22, 2023. The analyst firm set a price target for $16.00 expecting RVNC to rise to within 12 months (a possible 121.30% upside). 29 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Revance Therapeutics (RVNC)?
The latest analyst rating for Revance Therapeutics (NASDAQ: RVNC) was provided by Mizuho, and Revance Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Revance Therapeutics (RVNC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Revance Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Revance Therapeutics was filed on November 22, 2023 so you should expect the next rating to be made available sometime around November 22, 2024.
Is the Analyst Rating Revance Therapeutics (RVNC) correct?
While ratings are subjective and will change, the latest Revance Therapeutics (RVNC) rating was a maintained with a price target of $35.00 to $16.00. The current price Revance Therapeutics (RVNC) is trading at is $7.23, which is out of the analyst's predicted range.